Preview

Пульмонология

Расширенный поиск

Профиль соотношения «польза / риск» для трехкомпонентной терапии единым ингалятором при лечении больных хронической обструктивной болезнью легких

https://doi.org/10.18093/0869-0189-2021-31-5-645-652

Полный текст:

Аннотация

Хроническая обструктивная болезнь легких (ХОБЛ) характеризуется существенной нагрузкой на систему здравоохранения и значительным социально-экономическим бременем. Международные медицинские общества рекомендуют индивидуальный подход к лечению и ведению пациентов, направленный как на уменьшение выраженности симптомов, так и снижение риска обострений. За последние годы опубликованы многочисленные клинические исследования по изучению эффективности и безопасности назначения пациентам с ХОБЛ трехкомпонентной терапии с применением единого ингалятора (Single-Inhaler Triple Therapy – SITT), включающей в себя длительно действующий антихолинергический препарат, длительно действующий β2-агонист и ингаляционный глюкокортикостероид (иГКС).

Целью данной публикации явился обзор рандомизированных контролируемых исследований, по данным которых продемонстрирована польза SITT, а также оценка этой пользы по сравнению с описанным риском развития пневмонии при применении иГКС.

Заключение. Ключевыми преимуществами SITT является значимое снижение частоты обострений, в т. ч. при которых потребовалась госпитализация. Кроме того, согласно полученным данным, отмечается снижение общей летальности. Польза этих преимуществ в большинстве случаев превалирует над риском увеличения частоты пневмонии, являющимся общеклассовым эффектом иГКС при ХОБЛ.

Об авторах

С. И. Овчаренко
Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения
Россия

Овчаренко Светлана Ивановна – д. м. н., профессор кафедры факультетской терапии № 1

19991, Москва, ул. Трубецкая, 8, стр. 2

тел.: (499) 248-56-67


Конфликт интересов:

Овчаренко С.И. – чтение лекций для компаний Novartis, AstraZeneca, Boehringer Ingelheim, ООО «Кьези Фармасьютикалс»; Белевский А.С. – чтение лекций для компаний Merck&Co, GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, ООО «Кьези Фармасьютикалс».



А. С. Белевский
Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения
Россия

Белевский Андрей Станиславович – д. м. н., профессор, заведующий кафедрой пульмонологии

19991, Москва, ул. Трубецкая, 8, стр. 2

тел.: (495) 963-24-67


Конфликт интересов:

Овчаренко С.И. – чтение лекций для компаний Novartis, AstraZeneca, Boehringer Ingelheim, ООО «Кьези Фармасьютикалс»; Белевский А.С. – чтение лекций для компаний Merck&Co, GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, ООО «Кьези Фармасьютикалс».



Список литературы

1. World Health Organization (WHO). Health statistics and information systems: projections of mortality and causes of death, 2016 to 2060. 2016. Available at: https://www.who.int/healthinfo/global_burden_disease/projections/en/ [Accessed: February 11, 2021].

2. Fletcher M.J., Upton J., Taylor-Fishwick J. et al. COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health. 2011; 11: 612. DOI: 10.1186/1471-2458-11-612.

3. Global Initiative for Chronic Obstructive Lung Disease (COLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2021 Report. Available at: https://goldcopd.org/2021-gold-reports/ [Accessed: May 11, 2021].

4. Guarascio A.J., Ray S.M., Finch C.K., Self T.H. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon. Outcomes Res. 2013; 5: 235–245.https://doi.org/10.2147/CEOR.S34321.

5. Miller J.D., Foster T., Boulanger L. et al. Direct costs of COPD in the U.S.: an analysis of Medical Expenditure Panel Survey (MEPS) data. COPD. 2005; 2 (3): 311–318. DOI: 10.1080/15412550500218221.

6. Miravitlles M., Murio C., Guerrero T., Gisbert R. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002; 121 (5): 1449–1455. DOI: 10.1378/chest.121.5.1449.

7. Strassels S.A., Smith D.H., Sullivan S.D., Mahajan P.S. The costs of treating COPD in the United States. Chest. 2001; 119 (2): 344–352. DOI: 10.1378/chest.119.2.344.

8. Rehman A.U., Ahmad Hassali M.A., Muhammad S.A. et al. The economic burden of chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature. Expert Rev. Pharmacoecon. Outcomes Res. 2020: 20 (6): 661–672. DOI: 10.1080/14737167.2020.1678385.

9. Chenna P.R., Mannino D.M. Outcomes of severe COPD exacerbations requiring hospitalization. Semin. Respir. Crit. Care Med. 2010; 31 (3): 286–294.https://doi.org/10.1055/s-0030-1254069.

10. Halpin D.M., Decramer M., Celli B. et al. Exacerbation frequency and course of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2012; 7: 653–661. DOI: 10.2147/COPD.S34186.

11. Halpin D.M., Miravitlles M., Metzdorf N., Celli B. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int. J. Chron. Obstruct Pulmon. Dis. 2017; 12: 2891–2908. DOI: 10.2147/COPD.S139470.

12. Fitch K., Iwasaki K., Pyenson B. et al. Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis. Curr. Med. Res. Opin. 2011; 27 (7): 1425–1429. DOI: 10.1185/03007995.2011.583230.

13. Ferguson G.T., Rabe K.F., Martinez F.J. et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018; 6 (10): 747–758. DOI: 10.1016/S2213-2600(18)30327-8.

14. Lipson D.A., Barnacle H., Birk R. et al. FULEIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am. J. Respir Crit. Care Med. 2017; 196 (4): 438–446. DOI: 10.1164/rccm.201703-0449OC.

15. Lipson D.A., Barnhart F., Brealey N. et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 2018; 378 (18): 1671–1680. DOI: 10.1056/NEJMoa1713901.

16. Papi A., Vestbo J., Fabbri L. et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018; 391 (10125): 1076–1084. DOI:10.1016/S0140-6736(18)30206-X.

17. Rabe K.F., Martinez F.J., Ferguson G.T. et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N. Engl. J. Med. 2020; 383 (1): 35–48. DOI: 10.1056/NEJMoa1916046.

18. Singh D., Papi A., Corradi M. et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016; 388 (10048): 963–973. DOI:10.1016/S0140-6736(16)31354-X.

19. Vestbo J., Fabbri L., Papi A. et al. Inhaled corticosteroid containing combinations and mortality in COPD. Eur. Respir. J. 2018; 52 (6): 1801230. DOI:10.1183/13993003.01230-2018.

20. Agusti A., Fabbri L.M., Singh D. et al. Inhaled corticosteroids in COPD: friend or foe? Eur. Respir. J. 2018; 52 (6): 1801219. DOI: 10.1183/13993003.01219-2018.

21. Lipworth B., Kuo C.R., Jabbal S. Current appraisal of single inhaler triple therapy in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 3003–3009. DOI: 10.2147/COPD.S177333.

22. Vanfleteren L., Fabbri L.M., Papi A. et al. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 3971–3981. DOI: 10.2147/COPD.S185975.

23. Mammen M.J., Lloyd D.R., Kumar S. et al. Triple therapy versus dual or monotherapy with long-acting bronchodilators for chronic obstructive pulmonary disease. A systematic review and meta-analysis. Ann. Am. Thorac. Soc. 2020; 17 (10): 1308–1318. DOI: 10.1513/AnnalsATS.202001-023OC.

24. Hartley B.F., Barnes N.C., Lettis S. et al. Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis. Respir. Res. 2020; 21 (1): 5. DOI: 10.1186/s12931-019-1262-0.

25. European Medicines Agency (EMA). Pharmacovigilance Risk Assessment Committee (PRAC), recommendation 2016. Inhaled corticosteroids (ICS) containing medicinal products indicated in the treatment of chronic obstructive pulmonary disease (COPD). Available at: https://www.ema.europa.eu/en/medicines/human/referrals/inhaled-corticosteroids-containing-medicinal-products-indicated-treatment-chronic-obstructive [Accessed: February 11, 2021].

26. European Medicines Agency (EMA). Committee for Medicinal Products for Human Use (CHMP). International non-proprietary name: beclometasone dipropionate/formoterol fumarate dehydrate/glycopyrronium. Assessment report 2018. Procedure No.EMEA/H/C/004257/II/0002. Available at: https://www.ema.europa.eu/en/documents/variation-report/trimbow-h-c-4257-ii-0002-epar-assessmentreport-variation_en.pdf [Accessed: February 11, 2021].

27. Han M.K., Criner G.J., Dransfield M.T. et al. The effect of inhaled corticosteroid withdrawal and baseline inhaled treatment on exacerbations in the IMPACT study. A randomized, double-blind, multicenter clinical trial. Am. J. Respir. Crit. Care Med. 2020; 202 (9): 1237–1243. DOI: 10.1164/rccm.201912-2478OC.

28. EU Clinical Trials Register. A multinational, multicentre, randomised, open-label, active-controlled, 26-week, 2-arm, parallel group study to evaluate the non-inferiority of fixed combination of beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide administered via pMDI (CHF 5993) versus fixed combination of fluticasone furoate plus vilanterol administered via DPI (Relvar®) plus tiotropium bromide (Spiriva®) for the treatment of patients with chronic obstructive pulmonary disease. EudraCT No.2014-001487-35. Available at: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001487-35/LT [Accessed: February 11, 2021].

29. Gershon A.S., Guan J., Victor J.C. et al. Quantifying health services use for chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2013; 187 (6): 596-601. DOI: 10.1164/rccm.201211-2044OC.

30. Johannesdottir S.A., Christiansen C.F., Johansen M.B. et al. Hospitalization with acute exacerbation of chronic obstructive pulmonary disease and associated health resource utilization: a population-based Danish cohort study. J. Med. Econ. 2013; 16 (7): 897–906. DOI: 10.3111/13696998.2013.800525.

31. Soler-Cataluna J. J, Martinez-Garcia M.A., Roman S. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60 (11): 925–931. DOI: 10.1136/thx.2005.040527.

32. Soler-Cataluna J.J., Martinez-Garcia M.A., Sanchez L.S. et al. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir. Med. 2009; 103 (5): 692–699. DOI: 10.1016/j.rmed.2008.12.005.

33. Rothnie K.J., Mullerova H., Smeeth L., Quint J.K. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2018; 198 (4): 464–471. DOI: 10.1164/rccm.201710-2029OC.

34. Lipson D.A., Crim C., Criner G.J. et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am. J. Respir.Crit. Care Med. 2020; 201 (12): 1508-1516. DOI: 10.1164/rccm.201911-2207OC.

35. Anthonisen N.R., Skeans M.A., Wise R.A. et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142 (4): 233–239. DOI: 10.7326/0003-4819-142-4-200502150-00005.

36. Yusuf S., Sleight P., Pogue J. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 2000; 342 (3): 145–153. DOI: 10.1056/NEJM200001203420301.

37. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360 (9326): 7–22. DOI: 10.1016/S0140-6736(02)09327-3.

38. Calverley P.M.A., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J Med. 2007; 356 (8): 775–789. DOI: 10.1056/NEJMoa063070.

39. Vestbo J., Anderson J.A., Brook R.D. et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016; 387 (10030): 1817–1826. DOI: 10.1016/S0140-6736(16)30069-1.

40. Williams N.P., Coombs N.A., Johnson M.J. et al. Seasonality, risk factors and burden of community-acquired pneumonia in COPD patients: a population database study using linked health care records. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 313–322. DOI: 10.2147/COPD.S121389.

41. Vestbo J., Papi A., Corradi M. et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017; 389 (10082): 1919–1929. DOI: 10.1016/S0140-6736(17)30188-5.

42. Dransfield M.T., Bourbeau J., Jones P.W. et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013; 1 (3): 210–223. DOI: 10.1016/S2213-2600(13)70074-2.

43. Williams N.P., Ostridge K., Devaster J.M. et al. Impact of radiologically stratified exacerbations: insights into pneumonia aetiology in COPD. Respir. Res. 2018; 19 (1): 143. DOI: 10.1186/s12931-018-0842-8.

44. Saleh A., Lopez-Campos J.L., Hartl S. et al. The effect of incidental consolidation on management and outcomes in COPD exacerbations: data from the European COPD audit. PLoS One. 2015; 10 (7): e0134004. DOI: 10.1371/journal.pone.0134004.

45. Dransfield M.T., Crim C., Criner G.J. et al. Risk of exacerbation and pneumonia with single-inhaler triple versus dual therapy in IMPACT. Ann. Am. Thorac. Soc. 2021; 18 (5): 788–798. DOI: 10.1513/AnnalsATS.202002-096OC.

46. Pascoe S., Barnes N., Brusselle G. et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir. Med. 2019; 7 (9): 745–756. DOI: 10.1016/S2213-2600(19)30190-0.

47. Bafadhel M., Peterson S., De Blas M.A. et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir. Med. 2018; 6 (2): 117–126. DOI: 10.1016/S2213-2600(18)30006-7.

48. Pascoe S., Pavord I., Hinds D. et al. The association between blood eosinophils and risk and treatment outcome in COPD is not dichotomised. Lancet Respir. Med. 2018; 6 (5): e18. DOI: 10.1016/S2213-2600(18)30137-1.

49. Halpin D.M.G., Worsley S., Ismaila A.S. et al. Intrepid: clinical effectiveness of once-daily single-inhaler fluticasone furoate/umeclidinium/ vilanterol versus multiple-inhaler triple therapy in usual clinical practice. Am. J. Respir. Crit. Care Med. 2020; 201: A4313. DOI: 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A4313.


Для цитирования:


Овчаренко С.И., Белевский А.С. Профиль соотношения «польза / риск» для трехкомпонентной терапии единым ингалятором при лечении больных хронической обструктивной болезнью легких. Пульмонология. 2021;31(5):645-652. https://doi.org/10.18093/0869-0189-2021-31-5-645-652

For citation:


Ovcharenko S.I., Belevskiy A.S. Benefit/risk ratio profile of single inhaler triple therapy for сhronic obstructive pulmonary disease patients. PULMONOLOGIYA. 2021;31(5):645-652. (In Russ.) https://doi.org/10.18093/0869-0189-2021-31-5-645-652

Просмотров: 125


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)